OPIS policy paper on legalising psilocybin for cluster headaches

10 November 2020

OPIS has released a policy paper that calls for legalising access to psilocybin and related substances for the treatment of cluster headaches, one of the most excruciating conditions known to medicine. Policy recommendations include allowing doctors to prescribe currently restricted substances such as psilocybin, LSD, DMT and 5-MeO-DALT to patients with cluster headaches and ensuring that these substances can be readily produced or imported for such medical use. It is also recommended to modify regulations to ensure that patients who purchase or possess small amounts of psychoactive substances for personal therapeutic use cannot be charged with a crime or offence. The policy paper, which summarises existing evidence and contains numerous patient testimonials, was co-signed by several prominent neurologists, ethicists and other experts.

The policy paper is available in English and Spanish. We also produced a Finnish version in close collaboration with the Finnish Horton Association.

The press release is available in English, French and Spanish.

OPIS has also produced a 2-minute animated video that vividly explains the issue: